cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Nurhadiyahya
Contact Email
nurhadiyahya@ugm.ac.id
Phone
+6289672800034
Journal Mail Official
ijpther@ugm.ac.id
Editorial Address
Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.4468
Core Subject : Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Neuroscience
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which managed by Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada. IJPTher is an open-access, and double-blind peer-reviewed journal published twice Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol 2 No 3 (2021): Special Issue: COVID-19" : 5 Documents clear
The potential of polyphenols from natural ingredients against SARS-CoV-2 infection: A review Made Agus Hendrayana; I Made Jawi; Dewa Made Sukrama; Dewa Ngurah Suprapta
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (355.803 KB) | DOI: 10.22146/ijpther.2310

Abstract

All countries in the world are facing the coronavirus disease-19 (COVID-19) pandemic which has resulted in various crises. To date, there is no effective treatment in controlling COVID-19. Many clinical trials of approved drugs against COVID-19 were conducted. However, the results were inconclusive, even severe adverse effects were reported. The new effective drugs are therefore urgently needed. Herbal medicines have been widely used by community to enhance the body immune system during COVID-19 pandemic. Polyphenols are large group of active compounds found in the natural ingredients. These compounds have been proven to have biological activity against various pathogen infections including viral infection. During COVID-19 pandemic, various polyphenol compounds from various medicinal plants have been investigated for their activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) both in silico and in vitro. Among the polyphenols investigated, some of them namely papyriflavonol, catechin gallate, gallocatechin gallate, luteolin, quercetin, tangeretin, naringenin, herbacetin, emodin, eriodyctiol, fenoterol, baicalin, myricetin, quercetagetin exhibited strong activity against SARS-CoV-2. The possibilities of mechanism of actions as antiSARS-CoV-2 of these polyphenols were 1) bind to the N protein causing the inhibition of viral transcription and replication; 2) inhibit the binding of S protein to ACE2 receptors preventing the entry of the virus into the host cells; 3) inhibit 3CLpro function inhibiting the viral transcription and maturation; and 4) bind directly to the ACE2 receptor. In conclusion, some polyphenol compounds from nature ingredients are potential to develop to be future antiSARS-CoV-2. However, further the pre-clinical and clinical studies are required to strengthen existing evidence.
The comparison of colchicine and standard treatment in COVID-19 patients: A mini review Yasmeen Kwok; Dwi Aris Agung Nugrahaningsih; Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (267.724 KB) | DOI: 10.22146/ijpther.2381

Abstract

Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020. There are several drugs used at different stages of the disease, but none seem to be completely effective. In the absence of any known therapy, many drugs have been tested, including colchicine. Colchicine differs from these other therapies in having pleiotropic mechanism of action, being less potent on any single target, and being an oral agent. It is also a better option since colchicine is not immunosuppressive, is not known to increase risk of infection, and is inexpensive. The aim of this study was to provide evidence of the role of colchicine in improving clinical outcome and reducing death rate of COVID-19 patients through literature mini-review. A mini-review, composed of previous RCTs comparing the use of colchicine in COVID-19 with standard care or placebo under the keyword “COVID-19”, “COVID”, “coronavirus”, “SARS-CoV-2”, “coronavirus disease”, “Colchicine”, “CAS 64-86-8”, “standard treatment”, “standard care”, “standard of care”, “common treatment”, “placebo”, “clinical improvement”, and “clinical response”. The addition of colchicine to standard treatment can be beneficial in treating COVID-19. Studies included showed that colchicine has significantly improved time to clinical deterioration compared to the control group. Colchicine reduced the length of hospitalization and the need for supplemental oxygen therapy. One of the included studies mentioned that in outpatient settings, colchicine can prevent hospitalization and even death. Colchicine can improve the clinical outcome on CRP levels, the number of patients that need mechanical ventilation, and death rate in COVID-19 patients. The addition of colchicine to standard treatment should be considered to prevent clinical deterioration and death. Colchicine reduces the number of adverse effects in COVID-19 patients except for gastrointestinal adverse effects, especially diarrhea, which is consistently more common in the colchicine groups.
Molecular docking study of Indonesian phytochemicals as inhibitor of 6-HB formation by binding to HR1 subunit of SARSCOV-2 S2 protein Jeffry Julianus; Phebe Hendra; Maywan Hariono; Nico Frederick; Satrio Ardyantoro; Mustofa; Jumina
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (468.072 KB) | DOI: 10.22146/ijpther.2392

Abstract

Coronavirus disease 2019 (COVID-19) is still as global pandemic. No officially drugs to treat COVID-19 are available until now. Increasing number of patients and deaths trigger new antiCOVID-19 discovery efforts. In this study, we have conducted in silico screening employing molecular docking for Indonesian phytochemicals. Docking process was performed by employing AutoDock4 software on crystal structure 6VSB. Based on molecular docking results, several compounds had potential as antiCOVID-19 drugs, such as β-carotene, veramiline, ecliptalbine, betulinic acid, and lupeol. β-carotene was the most potential compound to treat COVID-19.
Clinical trial and therapeutical progress of COVID-19 treated with remdesivir: A review Anna Maria Manullang; Monia Agni Wiyatami; Muhammad Azril Hardiman Mahulauw
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (382.475 KB) | DOI: 10.22146/ijpther.2625

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that first reported in Wuhan City, China. Most confirmed cases of COVID-19 develop mild, moderate, severe to critical symptoms. One of the therapies given and of concern is remdesivir. Remdesivir is an antiviral with a broad spectrum that has activity against various types of viruses including Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV. The aim of this review was to evaluate the clinical trial and the therapeutical progress of remdesivir in the treatment of COVID-19 patients. Databases used for this review were Google Scholar, JAMA, PubMed and Science Direct library. The inclusion criteria were covering any literature using remdesivir in clinical studies and COVID-19 therapy published from December 2019 to October 2020. Overall no pattern of laboratory abnormalities and clinically significant changes in vital signs or ECG shifts was observed in patients receiving remdesivir. The decision to use remdesivir in COVID-19 treatment should consider its potential benefits and risks.
Current pharmacological treatments for COVID-19: A narrative review Sudi Indra Jaya; Yacobus Christian Prasetyo
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (236.196 KB) | DOI: 10.22146/ijpther.2881

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has lasted more than one year. The number of daily cases and the number of deaths is still changing dynamically. As of this writing, specific drugs for COVID-19 are not yet available. This review aims to describe the key clinical evidence in pharmacological treatments for COVID-19. The article search process was carried out on the PubMed database with a combination of keywords ((“COVID-19”) OR (“SARS-CoV-2”)) AND ((“treatment”) OR (“therapy”)). In this article, there were six drugs reviewed that is corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, and interleukin-6 (IL-6) receptor blockers. Hydroxychloroquine, lopinavir-ritonavir, remdesivir, and ivermectin were not recommended for COVID-19 treatments regardless of disease severity and duration of symptoms. Therefore, they were excluded from the list of drugs for the treatment of COVID-19 by World Health Organization (WHO) stated strong recommendations in favor of two drugs, namely systemic corticosteroids and IL-6 receptor blockers namely tocilizumab or sarilumab. Both of them are recommended for the treatment of patients with severe and critical covid-19 so they are included in the list of COVID-19 therapeutic drugs by WHO.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue